Piero Focaccia sang the song in 1963: “Don’t change this year, same beach, same sea, to be able to see you again, to return, to stay with you……!
And since 2016 we have been investing in the Nasdaq100 stock, GILEAD SCIENCESand he promptly gives us back some nice pieces of bread (profits) to stash in the cellar (in our current account of our subscribers). Obviously our investments range across different stocks from different US and European price lists, but this stock always gives us great satisfaction, provided we buy it at the right time (or times).
The theme behind this movement is well known: macro data that do not disappoint too much and a moderate drop in inflation, which suggest the growing possibility of the infamous “soft landing”, i.e. a situation in which inflation returns without the economy needing to slow down too much. The consequence of this is that central banks can relax and possibly cut rates at the slightest sign of weakness, or even just to adjust monetary policy to the inflationary picture. Therefore, we have certainly seen a top in interest rates, with the ECB starting to cut rates and most likely by the end of 2024 the FED will also start to cut rates to the benefit of companies, especially high-growth ones.
Our operational strategies allow us to continue the activity both in phases of market weakness and in the presence of markets with increasing relative strength, grinding target after target on our equity portfolios. Remember that our operational advice from LombardReport.com follows you everywhere, at work or on vacation, in the office or under the beach umbrella, just one click is enough to ensure you do not miss any opportunity to trade but also to earn.
And we come to one of the winning operations of this hot summer 2024 on the Historical Portfolio:
GILEAD SCIENCES, symbol: GILD, ISIN code: US3755581036is a stock included in the Historical portfolio of Lombardreport.com “traded” with the “Nasdaq Weekly” strategy. The stock is listed on the NASDAQ stock market in New York.
We bought the US title precisely on the day February 16, 2024, priced at $71.50 with the ‘Nasdaq Weekly’ strategy of the Historical Portfolio. After taking a risk in May with prices that had approached our STOP level, in mid-June the stock began an impressive ride recovering all the fictitious loss, managing to go to target at $76.87 on July 25, 2024the day we sold and made a good profit + 7.51%!
GILEAD SCIENCES is a biopharmaceutical company engaged in the discovery, development and commercialization of medicines in areas of unmet medical need. It has pursued and achieved medical innovations for over three decades, with the goal of creating a healthier world for all people. The company’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver disease, hematology, oncology, and inflammatory and respiratory diseases. It offers antiviral products under the brand names Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi and Vosevi. The company operates in over 35 countries worldwide, employs 18,000 people and was founded in 1987 and is headquartered in Foster City, California. Its market capitalization is over $97 billion.
In the Historical Portfolio there are two mechanical strategies with very quiet operations since they are based on a weekly time frame but, at the same time, the investment is short-term. One is reserved for operations on Italian, European and US stocks, with a yield that varies from 7 to 8%. The other is the famous “Nasdaq Weekly” present in our Portfolio for more than 7 years that invests in the stocks that are part of the Nasdaq100 index always in weekly mode, with a percentage of target operations that exceeds 90%. and with a yield of 7% per operation. Both strategies are easily replicable even by people with little experience or who are approaching the world of finance for the first time.
Below is the equity line updated as of July 22, 2024:
SUBSCRIBE TO LOMBARDREPORT.COM
ENTERING ON A RED CARPET!!
€219 worth when you subscribe for only €137!+
3 Stock Market Manuals + Free Operational Brochure of our Website
SHIPPING INCLUDED
DISCOVER THE PROMOTION HERE >>